What outcomes are important to patients with mild cognitive impairment or Alzheimer's disease, their caregivers, and health‐care professionals? A systematic review-Reference-Cited by-同舟云学术

What outcomes are important to patients with mild cognitive impairment or Alzheimer's disease, their caregivers, and health‐care professionals? A systematic review

Published:2019-01-09 Issue:1 Volume:11 Page:231-247
ISSN:2352-8729
Container-title:Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
language:en
Short-container-title:Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring

Author:

Tochel Claire¹,Smith Michael¹,Baldwin Helen¹²,Gustavsson Anders³⁴⁵,Ly Amanda¹,Bexelius Christin⁵,Nelson Mia¹,Bintener Christophe⁶,Fantoni Enrico⁷,Garre‐Olmo Josep⁸,Janssen Olin⁹,Jindra Christoph¹⁰,Jørgensen Isabella F.¹¹,McKeown Alex²,Öztürk Buket¹²,Ponjoan Anna⁸¹³,Potashman Michele H.¹⁴,Reed Catherine¹⁵,Roncancio‐Diaz Emilse⁷,Vos Stephanie⁹,Sudlow Cathie¹,

Affiliation:

1. Centre for Medical Informatics, Usher Institute of Population Health Sciences and Informatics, University of EdinburghEdinburghUK

2. University of OxfordOxfordUK

3. Quantify ResearchStockholmSweden

4. Department of Neurobiology, Care Sciences & SocietyKarolinska InstituteStockholmSweden

5. F. Hoffmann‐La Roche Ltd.BaselSwitzerland

6. Alzheimer EuropeLuxembourg CityLuxembourg

7. GE HealthcareLife SciencesAmershamUK

8. Girona Biomedical Research Institute (IdibGI)GironaCataloniaSpain

9. Department of Psychiatry & NeuropsychologySchool for Mental Health & Neuroscience, Alzheimer Center Limburg, Maastricht UniversityMaastrichtthe Netherlands

10. Department of PsychiatryUniversity of OxfordOxfordUK

11. Novo Nordisk Foundation Center for Protein ResearchFaculty of Health & Medical SciencesUniversity of CopenhagenCopenhagenDenmark

12. Department of Clinical EpidemiologyAarhus University HospitalAarhusDenmark

13. Vascular Health Research Group (ISV‐Girona), Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol)BarcelonaCataloniaSpain

14. BiogenCambridgeMAUSA

15. Eli Lilly and Company LimitedWindleshamUK

Funder

Innovative Medicines Initiative

European Federation of Pharmaceutical Industries and Associations

EFPIA

Publisher

Wiley

Subject

Psychiatry and Mental health,Clinical Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1016/j.dadm.2018.12.003

Reference46 articles.

1. M.J.Prince.World Alzheimer Report 2015: the global impact of dementia: an analysis of prevalence incidence cost and trends.Alzheimer's Dis Int 2015;1–87

2. Defeating Alzheimer's disease and other dementias: a priority for European science and society

3. Alzheimer's disease

4. Outcomes Assessment in Clinical Trials of Alzheimer's Disease and its Precursors: Readying for Short‐term and Long‐term Clinical Trial Needs;Posner H.;Innov Clin Neurosci,2017

5. The ADAS-cog in Alzheimer's disease clinical trials: psychometric evaluation of the sum and its parts

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessing the clinical meaningfulness of slowing CDR-SB progression with disease-modifying therapies for Alzheimer disease;2024-07-16

2. Developing a core outcome set for interventions in people with mild cognitive impairment: study protocol;2024-07-05

3. Exploring Scaffolding Techniques for Agent-Administered Brief Cognitive Screening in Hospital Settings;Designing Interactive Systems Conference;2024-07

4. Understanding treatment goals and their application in clinical trial design for patients with Alzheimer disease and caregivers;Drugs in Context;2024-04-29

5. Mobility-Based Smartphone Digital Phenotypes Unobtrusively Capture Everyday Cognition, Mood, and Community Life-Space in Older Adults: A Pilot Study (Preprint);2024-04-29